^
Association details:
| Biomarker: | AGK-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Excerpt:
The AGK-BRAF expressing C0902 cell line showed increased sensitivity to the type II RAF inhibitor sorafenib (IC50 = 410 nM) compared to the BRAFV600E mutant melanoma cell lines A375 (IC50 = 3.0 µM) and SK-MEL-28 (IC50 = 3.1 µM). In contrast, the C0902 cell line showed relative resistance to the type I inhibitor vemurafenib (IC50 = 5.0 µM) compared to the BRAFV600E mutant cell lines (IC50 = 80–92 nM)...
DOI:
10.1111/pcmr.12148
